The United States Food and Drug Administration (FDA) announced on Wednesday that a specific batch of Xanax XR, a widely-used extended-release anti-anxiety medication, is being voluntarily recalled nationwide due to failure to meet required quality standards.
The recall is being initiated by Viatris Specialty, a company based in West Virginia, which currently manufactures the product.
This decision exclusively impacts batch number 8177156, which includes three-milligram tablets packaged in bottles of 60, with an expiration date of February 28, 2027.
According to the official statement, the medication was pulled because it failed to meet dissolution specifications, indicating that the tablets do not dissolve at the necessary standard rate, potentially failing quality control tests.
The affected batch was distributed across the United States from August 27, 2024, to May 29, 2025.
The formal recall process began on April 8, although Viatris started the voluntary procedure at the end of March.
The FDA has classified the product as Class II, meaning it may lead to temporary or medically reversible adverse health consequences but does not pose an immediate serious or fatal risk.
As of the announcement, there have been no reports of illnesses or injuries related to the recalled batch.
The recall is highly specific and does not affect any other batches of Xanax XR or generic Alprazolam, which constitute the vast majority of sales in the country.
A Viatris spokesperson clarified, "The voluntary recall of Xanax XR pertains solely to one batch of a single strength of the branded product, and no other batches of Xanax XR or its generics are impacted."
Both Viatris and the FDA agree that patients taking the affected batch do not need to take any immediate action.
The FDA further cautioned, "In some cases, stopping a medication can be more harmful to health than continuing to take the recalled drug."
Understanding the Xanax XR Recall in the U.S.
What is the reason for the Xanax XR recall?
The recall is due to the medication failing to meet dissolution specifications, meaning it does not dissolve at the required rate, potentially affecting its quality and efficacy.
Which batch of Xanax XR is affected by the recall?
The recall affects only batch number 8177156, which consists of three-milligram tablets in bottles of 60, with an expiration date of February 28, 2027.
Are there any health risks associated with the recalled batch?
The FDA classified the recall as Class II, indicating potential temporary or medically reversible adverse health consequences, but no immediate serious risks.
What should patients do if they are taking medication from the affected batch?
Patients using the affected batch are advised not to take any immediate action. Stopping medication without consulting a healthcare provider could be more harmful than continuing it.